(secondQuint)Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma.

 To participate in this study, patients must have disease that can be measured on a CT scan.

 Brain metastases are OK if stable.

 Pregnant and/or nursing women may not participate.

 This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer.

 Its efficacy in lung cancer in currently unknown.

 Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.

.

 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma@highlight

This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer.

 The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

